Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

CAH Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

CAH
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

CAH Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

CAH

$232.47
+$1.23 (0.53%)+0.53%
Open
Loading chart...
IndexN/A
Market Cap54.45B
Enterprise Value61.16B
Income$1.56B
Sales$222.58B
Employees47,922
P/E22.29
P/S0.22
P/B-19.45
P/C12.39
EV/EBITDA17.58
EV/Sales0.76
EPS (ttm)10.43
Earnings2025-10-30
Gross Margin3.67%
Oper. Margin1.02%
Profit Margin0.70%
Volume0.54M
Shs Outstand0.23B
Change0.54%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD3.27%
Perf Year68.25%
Perf 3Y178.00%
Perf 5Y287.61%
Perf 10Y160.42%
IPO1983-08-04
Income Statement by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Revenue$222.58B$226.83B$204.98B$181.33B$162.47B$152.92B$145.53B$136.81B
Cost of Revenue$214.41B$219.41B$198.09B$174.84B$155.69B$146.05B$138.70B$129.63B
Gross Profit$8.17B$7.41B$6.89B$6.48B$6.78B$6.87B$6.83B$7.18B
Gross Margin3.67%3.27%3.36%3.58%4.17%4.49%4.70%5.25%
Operating Expenses$5.89B$6.17B$6.14B$7.09B$6.31B$10.97B$4.77B$7.05B
Operating Income$2.27B$1.24B$752.00M$-607.00M$472.00M$-4.10B$2.06B$126.00M
Operating Margin1.02%0.55%0.37%-0.33%0.29%-2.68%1.42%0.09%
Net Income$1.56B$852.00M$330.00M$-938.00M$611.00M$-3.69B$1.36B$256.00M
Net Margin0.70%0.38%0.16%-0.52%0.38%-2.41%0.94%0.19%
EPS (Basic)$6.48$3.48$1.26$-3.34$2.09$-12.60$4.54$0.82
EBITDA$3.11B$1.96B$1.44B$55.00M$1.29B$-2.62B$3.04B$1.13B
Stock Option Compensation Expense$244.00M$121.00M$96.00M$0.00$89.00M$90.00M$82.00M$85.00M
Price To Earnings Ratio25.9428.1174.80-15.5527.28-4.1410.4759.70
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market Capitalization$40.49B$23.95B$24.68B$14.58B$16.67B$15.29B$14.27B$15.28B
Balance Sheet by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$53.12B$45.12B$43.35B$43.88B$44.45B$40.77B$40.96B$39.95B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$55.76B$48.33B$46.31B$44.58B$42.66B$38.97B$34.63B$33.89B
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$-2.78B$-3.21B$-2.96B$-709.00M$1.79B$1.79B$6.33B$6.06B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$-2.78B$-3.21B$-2.96B$-709.00M$1.79B$1.79B$6.33B$6.06B
Total Liabilities & Stockholders Equity$53.12B$45.12B$43.35B$43.88B$44.45B$40.77B$40.96B$39.95B
Book Value Per Share$-10.93$-13.11$-11.33$-2.53$6.14$6.12$21.10$19.36
Tangible Book Value Per Share$-61.46$-39.44$-34.64$-29.87$-28.42$-32.37$-18.26$-19.71
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on Assets2.94%1.89%0.76%-2.14%1.37%-9.06%3.33%0.64%
Return on Equity-56.13%-26.52%-11.16%132.30%34.12%-206.43%21.54%4.23%
Return on Invested Capital11.37%8.80%3.58%-4.33%2.65%-23.38%9.28%-0.79%
Quick Ratio0.500.560.520.570.600.540.540.53
Current Ratio0.940.981.001.081.121.101.071.07
Cash Flow by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Net Income$1.56B$852.00M$330.00M$-938.00M$611.00M$-3.69B$1.36B$256.00M
Depreciation$790.00M$710.00M$692.00M$692.00M$783.00M$913.00M$1.00B$1.03B
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$2.40B$3.76B$2.84B$3.12B$2.43B$1.96B$2.72B$2.77B
Capital Expenditures$547.00M$511.00M$481.00M$387.00M$400.00M$375.00M$328.00M$384.00M
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends Paid$494.00M$499.00M$525.00M$559.00M$573.00M$569.00M$577.00M$581.00M
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref Stock$765.00M$750.00M$2.00B$1.00B$200.00M$350.00M$600.00M$550.00M
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash Flow$1.85B$3.25B$2.36B$2.73B$2.03B$1.58B$2.39B$2.38B
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Jul 3 · 4:30AM[Latest] Global Gauze Bandage Rolls Market Size/Share Worth USD 3.19 Billion by 2035 at a 4.97% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc. ↗Jun 8 · 11:00AM[Latest] Surgical Masks Market Size Will Attain USD 6.76 Billion by 2034 Registering a Promising CAGR of 5.5% - Exclusive Report by ZMR | Global Surgical Masks Market Size, Share, Trends Analysis ReportGlobeNewswire Inc. ↗May 8 · 8:47AMPregnancy Detection Kits Market Analysis Report 2026 - Competitive Landscape, Opportunities, and Forecasts, 2021-2025 & 2025-2031GlobeNewswire Inc. ↗May 5 · 8:40PMCardinal Health Board of Directors Approves Quarterly DividendBenzinga ↗Apr 30 · 5:09PMStock Market Today: Dow Jones Roars As Industrials Rescue Wall Street From Meta-Led Tech SlideBenzinga ↗Apr 30 · 3:20PMWhy Is Cardinal Health Stock Sinking Thursday?Benzinga ↗Apr 24 · 1:57PMRadiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market DemandGlobeNewswire Inc. ↗Apr 9 · 8:57AMRobotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032GlobeNewswire Inc. ↗
Show 12 more stories↓
Apr 9 · 8:49AMBiopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research and Global Forecast Report 2026-2032GlobeNewswire Inc. ↗Mar 31 · 8:45PM3 Dividend Stocks With High Returns on Invested CapitalInvesting.com ↗Feb 27 · 3:55PMGlobal Medical Device Cleaning Market Poised for Strong Growth as Infection Control Mandates and Reprocessing Technologies Accelerate Adoption: Verified Market Research®GlobeNewswire Inc. ↗Feb 12 · 9:45PMCardinal Health Board of Directors Approves Quarterly DividendBenzinga ↗Feb 5 · 3:18PMCardinal Health Smashes 52-Week High After Strong QuarterBenzinga ↗Feb 5 · 6:15AMHow the Largest IPO of 2025 Could Be Healthy for Your PortfolioThe Motley Fool ↗Feb 4 · 4:00PMUnited States Personal Protective Equipment (Gowns, Masks, Face Shields and Others) Market Outlook to 2033GlobeNewswire Inc. ↗Jan 12 · 2:00PMAOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement CompaniesGlobeNewswire Inc. ↗Jan 10 · 3:50PMPharmaceutical Waste Management Market is expected to generate a revenue of USD 2631.59 Million by 2032, Globally, at 5.91% CAGR: Verified Market Research®GlobeNewswire Inc. ↗Dec 15 · 3:50PMAdhesive Bandages Market is expected to generate a revenue of USD 4.48 Billion by 2032, Globally, at 3.60% CAGR: Verified Market Research®GlobeNewswire Inc. ↗Dec 5 · 11:19PM3 No-Brainer Dividend Stocks to Buy Right NowThe Motley Fool ↗Nov 5 · 2:00PMIncreasing medication access: Charitable clinics and pharmacies to receive share in $1.6 million in Equity Rx grants from Cardinal Health FoundationGlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Hollar Jason M.
Award
188.0K
—
—
Aug 4, 26
Greene Michelle D.
Award
17.2K
—
—
Aug 4, 26
Alt Aaron E
Award
58.7K
—
—
Aug 4, 26
WEITZMAN DEBORAH
Award
54.8K
—
—
Aug 4, 26
Mason Stephen M
Award
47.0K
—
—
Aug 4, 26

Company

CEO: Jason HollarEmployees: 55392www.cardinalhealth.com
About the company↓

Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

Discover more

You may be interested in
ABX

Abacus Global Management Inc

$9.27

↑ 8.74%
CRM

Salesforce Inc

$197.12

↓ 2.11%
META

Meta Platforms Inc

$591.43

↓ 0.59%
JPM

JPMorgan Chase & Co

$362.66

↓ 0.12%
TSLA

Tesla Inc

$341.43

↑ 0.44%
MA

Mastercard Inc

$569.13

↑ 0.34%
MSFT

Microsoft Corp

$495.93

↓ 0.20%
BAC

Bank of America Corp

$64.38

↑ 0.46%
ADBE

Adobe Inc

$265.27

↓ 1.93%
PYPL

PayPal Holdings Inc

$60.00

↓ 0.97%
NVDA

NVIDIA Corp

$225.49

↑ 0.09%
INTC

Intel Corp

$102.88

↓ 1.56%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC

Why it moved over time

Catalyst history

4 entries
Aug 13, 2026
Earnings+0.00%

Cardinal Health (CAH) topped Q4 profit estimates and forecast fiscal 2027 profit above Street expectations, citing sustained specialty-drug demand—providing a stronger earnings-growth outlook for investors.

Key fact: Cardinal Health forecast fiscal 2027 profit above Wall Street expectations driven by sustained specialty drug demand.

reuters.com: Cardinal Health forecasts full-year profit above estimates on specialty drug strength↗
Aug 12, 2026
Earnings+1.30%

Cardinal Health (CAH) reported Q4 earnings that topped estimates and forecast fiscal 2027 profit well above expectations, citing strong specialty-drug demand, which improves its earnings outlook.

Key fact: Cardinal forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for specialty drugs.

reuters.com: Cardinal Health forecasts full-year profit above estimates on specialty drug strength↗
Aug 11, 2026
Earnings-0.00%

Cardinal Health (CAH) faces a fiscal Q4 earnings report before the Aug. 11 open, a catalyst because results and guidance could materially shift near-term earnings expectations and valuation.

Key fact: Cardinal Health will release fiscal Q4 results before the opening bell on Aug. 11, 2026.

benzinga.com: Cardinal Health Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts↗
Show 1 earlier catalysts↓
Aug 10, 2026
Earnings-0.53%

Cardinal Health (CAH) is in focus ahead of its Q4 earnings report, with investors watching pharma and specialty sales and higher-margin business strength to see if growth offsets pricing headwinds.

Key fact: Q4 results will show if pharma, specialty and higher-margin segments offset pricing headwinds.

zacks.com: Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?↗